KR20190016972A - 유전자에 기반한 염증성 장 질환의 진단 - Google Patents

유전자에 기반한 염증성 장 질환의 진단 Download PDF

Info

Publication number
KR20190016972A
KR20190016972A KR1020187037151A KR20187037151A KR20190016972A KR 20190016972 A KR20190016972 A KR 20190016972A KR 1020187037151 A KR1020187037151 A KR 1020187037151A KR 20187037151 A KR20187037151 A KR 20187037151A KR 20190016972 A KR20190016972 A KR 20190016972A
Authority
KR
South Korea
Prior art keywords
gene
ibd
subject
allele
locus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187037151A
Other languages
English (en)
Korean (ko)
Inventor
더모트 피 맥거번
달린 리
Original Assignee
세다르스-신나이 메디칼 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60326226&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20190016972(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 세다르스-신나이 메디칼 센터 filed Critical 세다르스-신나이 메디칼 센터
Priority to KR1020227003985A priority Critical patent/KR102481305B1/ko
Publication of KR20190016972A publication Critical patent/KR20190016972A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020187037151A 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단 Ceased KR20190016972A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227003985A KR102481305B1 (ko) 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662339357P 2016-05-20 2016-05-20
US62/339,357 2016-05-20
PCT/US2017/033625 WO2017201461A1 (en) 2016-05-20 2017-05-19 Diagnosis of inflammatory bowel disease based on genes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227003985A Division KR102481305B1 (ko) 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단

Publications (1)

Publication Number Publication Date
KR20190016972A true KR20190016972A (ko) 2019-02-19

Family

ID=60326226

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020187037151A Ceased KR20190016972A (ko) 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단
KR1020227003985A Active KR102481305B1 (ko) 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단
KR1020247019512A Ceased KR20240095363A (ko) 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단
KR1020227044940A Ceased KR20230003433A (ko) 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020227003985A Active KR102481305B1 (ko) 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단
KR1020247019512A Ceased KR20240095363A (ko) 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단
KR1020227044940A Ceased KR20230003433A (ko) 2016-05-20 2017-05-19 유전자에 기반한 염증성 장 질환의 진단

Country Status (6)

Country Link
US (2) US11549146B2 (https=)
EP (1) EP3458466B1 (https=)
JP (4) JP7475811B2 (https=)
KR (4) KR20190016972A (https=)
CN (2) CN109476698B (https=)
WO (1) WO2017201461A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
KR20240095481A (ko) 2016-03-17 2024-06-25 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
EP3458466B1 (en) * 2016-05-20 2024-08-07 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease based on genes
WO2020112890A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith
AU2020275413A1 (en) 2019-05-14 2021-12-23 Cedars-Sinai Medical Center TL1A patient selection methods, systems, and devices
BR112022025667A2 (pt) * 2020-06-26 2023-03-07 Pfizer Métodos de tratamento da doença inflamatória intestinal com anticorpos tl1a
AU2021377688A1 (en) * 2020-11-13 2023-06-29 Cedars-Sinai Medical Center Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
CN115851911B (zh) * 2022-11-25 2025-10-24 南京鼓楼医院 一种用于鉴别狼疮性肾炎的尿液外泌体tsRNA标志物和探针及其应用
WO2024148218A2 (en) * 2023-01-06 2024-07-11 Prometheus Biosciences, Inc. Methods of treating inflammatory diseases with combination of tl1a inhibitors and tnf inhibitors
CN121843714A (zh) 2023-08-11 2026-04-10 派拉冈医疗公司 Tl1a结合抗体及使用方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443421A (en) 1982-03-16 1984-04-17 Occidental Chemical Corporation Process for removing particulate impurities from aqueous phosphoric acid
DE3475880D1 (en) 1984-08-27 1989-02-09 Toray Industries Solid-liquid separating apparatus
US5000850A (en) 1986-09-10 1991-03-19 Engelhard Corporation Apparatus for dewatering an aqueous clay suspension
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
AU5052899A (en) * 1998-07-25 2000-02-21 Astrazeneca Ab Genetic polymorphisms in the human neurokinin 1 receptor gene and their uses in diagnosis and treatment of diseases
JP2004194534A (ja) 2002-12-17 2004-07-15 Sumitomo Pharmaceut Co Ltd 炎症性腸疾患疾患マーカーおよびその利用
ES2367566T3 (es) * 2003-10-06 2011-11-04 Novartis Ag Uso de polimorfismos genéticos que se asocian con la eficacia del tratamiento de una enfermedad inflamatoria.
EP1815021A2 (en) 2004-11-03 2007-08-08 Almac Diagnostics Limited Transcriptome microarray technology and methods of using the same
KR101443050B1 (ko) 2005-05-06 2014-09-22 지모제넥틱스, 인코포레이티드 Ｉｌ-31 단클론성 항체 및 사용법
US20090317388A1 (en) 2005-05-25 2009-12-24 Linda Burkly Tl1a in treatment of disease
EP1963534A2 (en) * 2005-12-19 2008-09-03 Genizon Biosciences Inc. Genemap of the human gene associated with crohn's disease
WO2008073303A2 (en) 2006-12-07 2008-06-19 Switchgear Genomics Transcriptional regulatory elements of biological pathways, tools, and methods
US20110217310A1 (en) 2007-01-10 2011-09-08 Siegel Richard M Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology
WO2008100913A2 (en) * 2007-02-12 2008-08-21 The Johns Hopkins University Early detection and prognosis of colon cancers
US20100190162A1 (en) 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2008106579A2 (en) 2007-02-28 2008-09-04 Cedars-Sinai Medical Center The role of il-12, il-23 and il-17 receptors in inflammatory bowel disease
US20150376707A1 (en) * 2007-05-18 2015-12-31 Cedars-Sinai Medical Center Methods of diagnosing and treating inflammatory bowel disease
WO2011088380A1 (en) * 2010-01-15 2011-07-21 Cedars-Sinai Medical Center Methods of using fut2 genetic variants to diagnose crohn's disease
US8118175B2 (en) 2007-07-18 2012-02-21 Siemens Industry, Inc. Venting device for a disc filter
WO2009039244A2 (en) * 2007-09-18 2009-03-26 Genizon Biosciences Inc. Genemap of the human genes associated with crohn's disease
US20100240043A1 (en) 2007-10-19 2010-09-23 Cedars-Sinai Medical Center Methods of using genetic variants to diagnose and predict inflammatory bowel disease
UA104132C2 (en) 2007-11-13 2014-01-10 Тева Биофармасьютикалз Юесей, Инк. Humanized antibodies against tl1a
CA2735578C (en) * 2008-08-12 2018-10-23 Zinfandel Pharmaceuticals, Inc. Method of identifying risk factors for alzheimer's disease comprising tomm40 gene variants
DK2329259T3 (en) 2008-08-29 2016-05-09 Janssen Biotech Inc MARKERS AND PROCEDURES FOR ASSESSING AND TREATING ULCERATIVE COLITIS AND RELATED DISEASES USING A 20-GEN PANEL
JP2010088432A (ja) 2008-09-09 2010-04-22 Kansetsu Saisei Kenkyusho:Kk Ｔｎｆ阻害薬治療による有効性・副作用発現に関する多型、およびその利用
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
US9580752B2 (en) * 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
WO2010120814A1 (en) 2009-04-14 2010-10-21 Prometheus Laboratories Inc. Inflammatory bowel disease prognostics
JP2013528389A (ja) * 2010-06-04 2013-07-11 ネステク ソシエテ アノニム 炎症性腸疾患の診断を改善させる方法
US8766034B2 (en) 2010-09-22 2014-07-01 Cedars-Sinai Medical Center TL1A model of inflammation fibrosis and autoimmunity
CA2817256A1 (en) 2010-11-12 2012-05-18 The General Hospital Corporation Polycomb-associated non-coding rnas
US9902996B2 (en) 2011-02-11 2018-02-27 Cedars-Sinai Medical Center Methods of predicting the need for surgery in crohn's disease
AU2012253422B2 (en) 2011-05-10 2015-08-13 Société des Produits Nestlé S.A. Methods of disease activity profiling for personalized therapy management
WO2012156515A1 (en) 2011-05-18 2012-11-22 Rheinische Friedrich-Wilhelms-Universität Bonn Molecular analysis of acute myeloid leukemia
WO2012161856A1 (en) 2011-05-20 2012-11-29 Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
CN103732623B (zh) 2011-06-03 2017-09-29 佐马技术有限公司 对TGF‑β具有特异性的抗体
JP2015502740A (ja) * 2011-10-21 2015-01-29 ネステク ソシエテ アノニム 炎症性腸疾患の診断を改善するための方法
WO2013117751A2 (en) * 2012-02-10 2013-08-15 Novo Nordisk A/S Methods related to treatment of inflammatory diseases and disorders
KR20230109779A (ko) 2013-03-27 2023-07-20 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전
ES2894963T3 (es) * 2013-05-17 2022-02-16 Cedars Sinai Medical Center Variantes de TNFSF15 y DcR3 asociadas con la enfermedad de Crohn
RU2683781C2 (ru) 2013-10-09 2019-04-02 Седарс-Синаи Медикал Сентер Диагностика и лечение синдрома раздраженного кишечника и воспалительного заболевания кишечника
EP3736344A1 (en) * 2014-03-13 2020-11-11 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
US20180305689A1 (en) 2015-04-22 2018-10-25 Mina Therapeutics Limited Sarna compositions and methods of use
EP3419932A4 (en) 2016-02-26 2019-09-04 Nanotech Energy, Inc. METHODS, DEVICES AND SYSTEMS FOR PROCESSING CARBON-CONTAINING COMPOSITIONS
EP3458466B1 (en) 2016-05-20 2024-08-07 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease based on genes
WO2018022982A1 (en) 2016-07-29 2018-02-01 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
KR20190082815A (ko) 2016-10-26 2019-07-10 세다르스-신나이 메디칼 센터 중화 항-tl1a 단일 클론 항체
WO2018204764A1 (en) 2017-05-05 2018-11-08 Camp4 Therapeutics Corporation Identification and targeted modulation of gene signaling networks
WO2020121618A1 (ja) 2018-12-14 2020-06-18 株式会社フジクラ フェルール、ファイバ付きフェルール及びファイバ付きフェルールの製造方法

Also Published As

Publication number Publication date
US11549146B2 (en) 2023-01-10
JP2024037945A (ja) 2024-03-19
EP3458466A1 (en) 2019-03-27
JP2019516375A (ja) 2019-06-20
KR20230003433A (ko) 2023-01-05
JP7475811B2 (ja) 2024-04-30
US12545959B2 (en) 2026-02-10
JP7392020B2 (ja) 2023-12-05
JP2022095688A (ja) 2022-06-28
US20230366028A1 (en) 2023-11-16
EP3458466A4 (en) 2020-03-04
CN109476698A (zh) 2019-03-15
JP2026048696A (ja) 2026-03-17
WO2017201461A1 (en) 2017-11-23
CN109476698B (zh) 2023-10-17
KR20240095363A (ko) 2024-06-25
KR102481305B1 (ko) 2022-12-26
CN117286238A (zh) 2023-12-26
EP3458466B1 (en) 2024-08-07
KR20220025122A (ko) 2022-03-03
US20190194754A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
US20250041457A1 (en) Use of adeno-associated viral vectors to correct gene defects/ express proteins in hair cells and supporting cells in the inner ear
KR102481305B1 (ko) 유전자에 기반한 염증성 장 질환의 진단
KR101708544B1 (ko) 세포 증식 질환을 분석하기 위한 방법 및 핵산
KR102046668B1 (ko) 암 대상자의 예후를 결정하기 위한 방법 및 핵산
CA2941594A1 (en) Genetic polymorphisms of the protein receptor c (procr) associated with myocardial infarction, methods of detection and uses thereof
CN107223159A (zh) 源自特定细胞类型的dna的检测及相关方法
KR20170086027A (ko) 신경발달 장애에서의 행동을 개선시키기 위한 박테리아를 포함하는 조성물 및 방법
KR20130123357A (ko) 저산소증과 관련된 질환의 진단방법 및 키트
AU2016325030A1 (en) Novel biomarkers and methods of treating cancer
WO2006022629A1 (en) Methods of identifying risk of type ii diabetes and treatments thereof
KR20090087486A (ko) 타입 ２ 당뇨병의 유전적 감수성 변이
CN101631876A (zh) 2型糖尿病的遗传易感性变体
AU2023203393A1 (en) Compositions and methods for screening and identifying clinically aggressive prostate cancer
AU2018360287B2 (en) Method for determining the response of a malignant disease to an immunotherapy
EP1729930A2 (en) Methods for identifying risk of osteoarthritis and treatments thereof
WO2006022636A1 (en) Methods for identifying risk of type ii diabetes and treatments thereof
WO2006022634A1 (en) Methods for identifying risk of type ii diabetes and treatments thereof
KR102642320B1 (ko) 항암제에 대한 내성 진단용 조성물
IL179831A (en) In vitro method for detecting the presence of or predisposition to autism or to an autism spectrum disorder, and an in vitro method of selecting biologically active compounds on autism or autism spectrum disorders
WO2006022638A1 (en) Methods for identifying risk of type ii diabetes and treatments thereof
WO2018209358A2 (en) Systemic delivery of polypeptides
US20030124536A1 (en) Diagnosis and treatment of vascular disease
CA2887830A1 (en) Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof
CN114053413A (zh) 一种col4a4基因作为急性缺血性卒中治疗靶点的应用
KR20150094601A (ko) 성별에 독립적인 연령 결정 방법

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181220

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200519

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210512

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20211106

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210512

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220204

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20211106

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210712

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200519

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20220303

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220207

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20211106

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210712

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20210512

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200519

X601 Decision of rejection after re-examination